JP2016531567A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531567A5
JP2016531567A5 JP2016531761A JP2016531761A JP2016531567A5 JP 2016531567 A5 JP2016531567 A5 JP 2016531567A5 JP 2016531761 A JP2016531761 A JP 2016531761A JP 2016531761 A JP2016531761 A JP 2016531761A JP 2016531567 A5 JP2016531567 A5 JP 2016531567A5
Authority
JP
Japan
Prior art keywords
domain
fusion protein
derivative
multimerization
multimerization domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016531761A
Other languages
English (en)
Japanese (ja)
Other versions
JP6543626B2 (ja
JP2016531567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/047852 external-priority patent/WO2015017214A1/en
Publication of JP2016531567A publication Critical patent/JP2016531567A/ja
Publication of JP2016531567A5 publication Critical patent/JP2016531567A5/ja
Application granted granted Critical
Publication of JP6543626B2 publication Critical patent/JP6543626B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016531761A 2013-07-29 2014-07-23 多部分シグナル伝達タンパク質およびその使用 Active JP6543626B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361859697P 2013-07-29 2013-07-29
US61/859,697 2013-07-29
US201461934092P 2014-01-31 2014-01-31
US61/934,092 2014-01-31
PCT/US2014/047852 WO2015017214A1 (en) 2013-07-29 2014-07-23 Multipartite signaling proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019112035A Division JP2019146598A (ja) 2013-07-29 2019-06-17 多部分シグナル伝達タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2016531567A JP2016531567A (ja) 2016-10-13
JP2016531567A5 true JP2016531567A5 (cg-RX-API-DMAC7.html) 2017-08-31
JP6543626B2 JP6543626B2 (ja) 2019-07-10

Family

ID=52432340

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016531761A Active JP6543626B2 (ja) 2013-07-29 2014-07-23 多部分シグナル伝達タンパク質およびその使用
JP2019112035A Withdrawn JP2019146598A (ja) 2013-07-29 2019-06-17 多部分シグナル伝達タンパク質およびその使用
JP2020092158A Active JP6748796B1 (ja) 2013-07-29 2020-05-27 多部分シグナル伝達タンパク質およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019112035A Withdrawn JP2019146598A (ja) 2013-07-29 2019-06-17 多部分シグナル伝達タンパク質およびその使用
JP2020092158A Active JP6748796B1 (ja) 2013-07-29 2020-05-27 多部分シグナル伝達タンパク質およびその使用

Country Status (8)

Country Link
US (6) US10196444B2 (cg-RX-API-DMAC7.html)
EP (2) EP3027204B1 (cg-RX-API-DMAC7.html)
JP (3) JP6543626B2 (cg-RX-API-DMAC7.html)
AU (2) AU2014296626B2 (cg-RX-API-DMAC7.html)
CA (1) CA2956667A1 (cg-RX-API-DMAC7.html)
DK (1) DK3027204T3 (cg-RX-API-DMAC7.html)
ES (1) ES2910004T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015017214A1 (cg-RX-API-DMAC7.html)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970468B1 (en) 2013-03-13 2021-07-07 Novartis AG Notch2 binding molecules for treating respiratory diseases
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
EP3105333B1 (en) 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US20220241327A1 (en) * 2015-06-25 2022-08-04 Icell Gene Therapeutics Llc Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof
EP3380602A4 (en) 2015-11-23 2019-09-25 Trustees of Boston University METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
CA3007473A1 (en) * 2015-12-14 2017-06-22 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
EP3184548A1 (en) 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
KR20250134722A (ko) 2016-02-12 2025-09-11 블루버드 바이오, 인코포레이티드. Vcn 인핸서 조성물 및 이의 사용 방법
US10871490B2 (en) 2016-02-29 2020-12-22 Multenyi Biotec, gmbH Assay for detection of chimeric antigen receptor T cells
AU2017240801A1 (en) 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
SG10201912519VA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric receptors and methods of use thereof
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
NZ746700A (en) 2016-04-01 2023-04-28 Kite Pharma Inc Bcma binding molecules and methods of use thereof
RU2018138122A (ru) 2016-04-05 2020-05-12 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новая терапия
CA3020993A1 (en) * 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
EP3500696A4 (en) 2016-08-16 2020-04-08 Bluebird Bio, Inc. VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE
US20190262398A1 (en) 2016-08-23 2019-08-29 Bluebird Bio, Inc. Tim3 homing endonuclease variants, compositions, and methods of use
SG11201901757YA (en) 2016-09-08 2019-03-28 Bluebird Bio Inc Pd-1 homing endonuclease variants, compositions, and methods of use
US11530395B2 (en) 2016-10-17 2022-12-20 2Seventy Bio, Inc. TGFBetaR2 endonuclease variants, compositions, and methods of use
CN109983027A (zh) * 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体
US11654158B2 (en) 2016-11-17 2023-05-23 2Seventy Bio, Inc. TGFBeta signal convertor
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
CA3045667A1 (en) 2016-12-13 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
AU2018221730B2 (en) 2017-02-15 2024-06-20 Novo Nordisk A/S Donor repair templates multiplex genome editing
BR102018006205A2 (pt) * 2017-03-28 2021-03-23 Cell Design Labs, Inc. Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos
BR102018008260A2 (pt) 2017-04-24 2020-04-28 Kite Pharma, Inc. domínios de ligação ao antígeno humanizado e métodos de uso
WO2018200582A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
AU2018270515A1 (en) * 2017-05-19 2019-12-05 The Regents Of The University Of California Antibody chemically induced dimerizer (abCID) as molecular switches for regulating cellular therapies
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
CN118853581A (zh) 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
TW201908335A (zh) * 2017-07-25 2019-03-01 美國德州系統大學評議委員會 增強之嵌合抗原受體及其用途
WO2019070740A2 (en) * 2017-10-02 2019-04-11 Fred Hutchinson Cancer Research Center LUTENING HORMONE RECEPTOR BINDING AGENTS AND LUTINISING HORMONE AGONISTS FOR IDENTIFICATION, MULTIPLICATION, REMOVAL AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
WO2019099707A1 (en) 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
CA3084551A1 (en) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
WO2019118885A1 (en) * 2017-12-14 2019-06-20 Bluebird Bio, Inc. Nkg2d daric receptors
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
CA3086032A1 (en) 2017-12-20 2019-06-27 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CR20200539A (es) 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso
SG11202009975TA (en) 2018-04-12 2020-11-27 Umoja Biopharma Inc Viral vectors and packaging cell lines
JP7584127B2 (ja) * 2018-04-26 2024-11-15 ベイラー カレッジ オブ メディスン 活性化された病原性t細胞およびnk細胞の選択的標的化のための自己/同種免疫防御受容体
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
MX2021000617A (es) 2018-07-18 2021-04-13 Amgen Inc Receptores quimericos de steap1 y metodos de uso de los mismos.
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
US11542305B2 (en) 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
JP2022513750A (ja) 2018-12-10 2022-02-09 2セブンティ バイオ インコーポレイテッド ホーミングエンドヌクレアーゼバリアント
CA3122094A1 (en) 2018-12-10 2020-06-18 Bluebird Bio, Inc. Pdcd-1 homing endonuclease variants
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020123947A1 (en) * 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020123933A1 (en) * 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
AU2019397152A1 (en) * 2018-12-14 2021-06-24 2Seventy Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020146627A1 (en) * 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
CN113710697A (zh) * 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
EP3959305A1 (en) 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
BR112021021178A2 (pt) 2019-04-26 2022-03-15 Allogene Therapeutics Inc Receptores de antígeno quimérico resistentes ao rituximabe e usos destes
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
CA3136737A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
CN114040926B (zh) 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
EP3966245A1 (en) 2019-05-04 2022-03-16 Inhibrx, Inc. Cd33-binding polypeptides and uses thereof
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
WO2020227475A1 (en) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cll-1 targeted immunotherapies
EP3966338A1 (en) * 2019-05-08 2022-03-16 Inhibrx, Inc. Cd123 targeted immunotherapies
MA55911A (fr) 2019-05-08 2022-03-16 2Seventy Bio Inc Lymphocytes t génétiquement modifiés
CN114206928B (zh) * 2019-05-08 2025-08-08 印希彼生物科学公司 Cd33靶向免疫疗法
US20220236257A1 (en) * 2019-06-05 2022-07-28 Yeda Research And Development Co. Ltd. Artificial receptors, recombinant cells comprising thereof, methods for their preparation, and method of using thereof
WO2021030153A2 (en) * 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021044439A1 (en) * 2019-09-08 2021-03-11 Immunoadaptive Cell Therapy Pvt Ltd. Inducible cytokine signals & methods for immunotherapy
KR20220070501A (ko) * 2019-09-30 2022-05-31 2세븐티 바이오, 인코포레이티드 이량체화제로 조절된 면역수용체 복합체
EP4045663A2 (en) * 2019-10-16 2022-08-24 Umoja Biopharma, Inc. Retroviral vector for univeral receptor therapy
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2021154839A1 (en) 2020-01-30 2021-08-05 Umoja Biopharma, Inc. Bispecific transduction enhancer
WO2021198163A1 (en) * 2020-04-01 2021-10-07 Medigene Immunotherapies Gmbh Cd3-fusion protein and uses thereof
EP3916388A1 (en) 2020-05-27 2021-12-01 Miltenyi Biotec B.V. & Co. KG Reagents for detection of chimeric antigen receptor cells
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
US20230272039A1 (en) 2020-07-16 2023-08-31 Umoja Biopharma, Inc. Gated adapter targeting receptor
EP4635972A3 (en) 2020-07-20 2025-12-24 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
WO2022099175A1 (en) * 2020-11-09 2022-05-12 2Seventy Bio, Inc. Cd33 targeted immunotherapies
KR20230156687A (ko) 2020-11-20 2023-11-14 우모자 바이오파마 인코포레이티드 다수 폴리뉴클레오티드들의 전달을 위한 벡터 시스템 및 그의 용도
WO2022109360A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US12540141B2 (en) 2020-11-23 2026-02-03 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
AU2021386370A1 (en) 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス,インコーポレイテッド プロテアーゼ活性化cd45ゲートcar
EP4286518A4 (en) * 2021-01-25 2025-05-21 Rznomics Inc. Immune checkpoint inhibitor expressing cancer-specific trans-splicing ribozyme and use thereof
CN116670172A (zh) * 2021-01-25 2023-08-29 尔知渃米斯股份有限公司 表达免疫检查点抑制剂的癌症特异性反式剪接核酶及其用途
KR102471898B1 (ko) * 2021-01-25 2022-12-06 알지노믹스 주식회사 면역관문 억제제를 발현하는 암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도
WO2022164935A1 (en) * 2021-01-27 2022-08-04 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US20230060292A1 (en) 2021-07-26 2023-03-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US20230112648A1 (en) * 2021-09-17 2023-04-13 Homology Medicines, Inc. Non-naturally occurring polyadenylation elements and methods of use thereof
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白18﹒2之嵌合抗原受體及結合劑以及其用途
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
US20250152743A1 (en) * 2023-11-13 2025-05-15 California Institute Of Technology Synpoptosis circuits for programmable cell death control

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1995A (en) 1841-03-03 Latch of door and other locks
US1999A (en) 1841-03-12 Improvement in seed-planters
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2128511C (en) * 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
US6972193B1 (en) * 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
HUT73101A (en) * 1993-02-12 1996-06-28 Harvard College Method for regulating transcription of targeted genes and other biological events
EP0737207B1 (en) 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
WO1999036553A2 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
JP2002503667A (ja) * 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
WO2010062966A2 (en) 2008-11-26 2010-06-03 The General Hospital Corporation Methods for inducing mixed chimerism
US9089520B2 (en) * 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
JP5897035B2 (ja) * 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド,ボルチモア 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
IL305629A (en) * 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
HK1220111A1 (zh) 2013-03-05 2017-04-28 Baylor College Of Medicine 人类t淋巴细胞中类肝素酶的表达
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2016014553A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors

Similar Documents

Publication Publication Date Title
JP7630190B2 (ja) Cd7を標的にするヒト化抗体及びその使用
AU2026200849A1 (en) Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US20240018251A1 (en) Bcma-targeting single-domain antibody and use thereof
AU2016343809B2 (en) Compositions and methods for treatment of cancer
JP2025065142A5 (cg-RX-API-DMAC7.html)
JP2022513460A5 (cg-RX-API-DMAC7.html)
JP2021519580A5 (cg-RX-API-DMAC7.html)
RU2018135819A (ru) Иммунные эффекторные клетки с отредактированным геномом
US20230390336A1 (en) Chimeric antigen receptor targeting cd7 and use thereof
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
JP6568239B2 (ja) T細胞受容体ライブラリ
JP2018525006A5 (cg-RX-API-DMAC7.html)
JP2015527070A5 (cg-RX-API-DMAC7.html)
HRP20201906T1 (hr) Označene kimerne efektorske molekule i njihovi receptori
JP2020517295A5 (cg-RX-API-DMAC7.html)
JP2019146598A (ja) 多部分シグナル伝達タンパク質およびその使用
JP2019518425A5 (cg-RX-API-DMAC7.html)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
RU2020135106A (ru) Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
JP2024534417A5 (cg-RX-API-DMAC7.html)
US20240052029A1 (en) Ror1-targeting antibody and use thereof
JP2024023228A5 (cg-RX-API-DMAC7.html)
JP2024534471A5 (cg-RX-API-DMAC7.html)
JP2016514462A5 (cg-RX-API-DMAC7.html)
JP2017527275A5 (cg-RX-API-DMAC7.html)